---
title: "Panbela Therapeutics, Inc. (PBLA.US)"
type: "quote"
locale: "en"
url: "https://longbridge.com/en/quote/PBLA.US.md"
symbol: "PBLA.US"
name: "Panbela Therapeutics, Inc."
industry: "生物技术"
---

# Panbela Therapeutics, Inc. (PBLA.US)

| Item | Detail |
|------|--------|
| Industry | 生物技术 |
| Location | 美股市场 |
| Website | [www.panbela.com](https://www.panbela.com) |

## Company Profile

Panbela Therapeutics, Inc.是一家临床阶段生物制药公司，致力于开发颠覆性治疗方案，用于治疗有迫切未满足医疗需求的患者。该公司的主力产品候选包括：
- Ivospemin (SBP-101)，一种专有的多胺类似物，已完成用于治疗转移性胰腺导管腺癌患者的 Ia/Ib 期临床试验；
- Flynpovi，一种依氟胺（CPP-1X）和舒林达克的组合，目前正在进行 III 期临床试验；
- Eflornithine，一种酶活化的鸟氨酸脱羧酶不可逆抑制剂，目前处于 I/II 期试验阶段。

该公司与约翰斯·霍普金斯大学医学院签订了研究协议，共同开发 ivospemin。该公司之前被...

## Valuation Analysis

| Metric | Current | Industry Ranking | High | Median | Low |
|--------|---------|-----------------|------|--------|-----|
| PE (TTM) | 0.00 | 71/605 | - | - | - |
| PB | 0.00 | 456/605 | - | - | - |
| Dividend Yield | 0.00% | - | - | - | - |

## Institutional View

### Analyst Rating Distribution

> As of 2024-09-25T04:00:00.000Z

Total Analysts: **1**

| Rating | Count | Percentage |
|--------|-------|-----------|
| Buy | 0 | 0% |
| Overweight | 1 | 100% |
| Hold | 0 | 0% |
| Underweight | 0 | 0% |
| Sell | 0 | 0% |

### Target Price Forecast

| Metric | Price |
|--------|-------|
| Current Price | 0.01 |

## References

- [Company Overview](https://longbridge.com/en/quote/PBLA.US/overview.md) - Shareholders, executives, business segments
- [Financials](https://longbridge.com/en/quote/PBLA.US/norm.md) - Income statement, balance sheet, cash flow, distribution plan
- [Topics & Discussions](https://longbridge.com/en/quote/PBLA.US/topics.md) - Community topics and discussions

---

> **Disclaimer**: This article is for reference only and does not constitute any investment advice.